Millie
your market intelligence analyst
Search Results
210 results
Your search is now limited to «Eli Lilly» expert search.
Korean Biomedical Review 10/14/2019 05:13
The Korean branch of Eli Lilly said it has presented the phase 4 IXORA-R study, which compared Taltz against Tremfya in people living with moderate to severe plaque psoriasis.
More from Korean Biomedical Review:
Pharmafile 10/14/2019 04:15
FDA approves Eli Lilly’s Reyvow for treatment of migraine in adults.
More from Pharmafile:
PR Newswire 10/12/2019 06:45
At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.
More from PR Newswire:
ETHealthWorld (India) 10/12/2019 02:00
Lilly acquired Reyvow, formerly called lasmiditan , in a deal worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early 2017.
More from ETHealthWorld (India):
BioPharma Dive 10/11/2019 17:30
As it's active in the central nervous system, Lilly studied the drug for abuse potential and found it to be associated with less drug liking than the sedative alprazolam, but more than placebo.
More from BioPharma Dive:
FiercePharmaManufacturing 10/11/2019 16:08
Eli Lilly is already working to grow market share for its migraine prevention med Emgality, but now the company has a new medicine to add to its suite.
More from FiercePharmaManufacturing:
CNBC - Business 10/11/2019 15:24
FDA approves new Eli Lilly drug to 'resolve' migraine pain in two hours.
More from CNBC - Business:
NASDAQ 10/11/2019 14:39
The drug, formerly called lasmiditan, has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults.
More from NASDAQ:
Seeking Alpha 10/11/2019 12:17
Eli Lilly (LLY) announced positive results from its phase 4 study treating patients with severe plaque psoriasis.
More from Seeking Alpha:
MarketWatch 10/03/2019 09:37
Eli Lilly and Co. said Thursday it is voluntarily delisting from the Euronext Paris exchange, citing low trading volume, costs and administrative requirements. The stock will continue to trade on the New York Stock Exchange, its primary listing exchange. Shareholders that own Lilly stock through Euroclear France can participate in a voluntary sales facility on the NYSE, or will be able to trade on the New York exchange following the delisting via their financial intermediary, the company said. Shares rose slightly Thursday, but are down 7% in 2019, while the S&P 500 has gained 15%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
More from MarketWatch:
STAT 10/02/2019 14:49
In a boost for pharma, a federal judge dismissed two lawsuits alleging drug makers devised schemes in which nurses were used illegally to boost prescriptions.
More from STAT:
Reuters.com 09/30/2019 16:09
DOJ wins dismissal of 'pro' whistleblower cases against Bayer, Eli Lilly.
More from Reuters.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications